NASDAQ:SBPH

Spring Bank Pharmaceuticals Stock Forecast, Price & News

$9.85

+0.72 (+7.89 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.32

Now: $9.85▼

$10.34

50-Day Range

$1.21

MA: $7.94▼

$10.39

52-Week Range

$0.80

Now: $9.85▼

$4.80

Volume97,166 shs

Average Volume177,606 shs

Market Capitalization$170.08 million

P/E RatioN/A

Dividend YieldN/A

Beta1.07

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

MarketRank^™

Overall MarketRank^™

0.77 out of 5 stars

Medical Sector

1133rd out of 1,928 stocks

Pharmaceutical Preparations Industry

522nd out of 774 stocks

1.0 Analyst's Opinion

Consensus Rating
Spring Bank Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.75, Spring Bank Pharmaceuticals has a forecasted downside of 82.2% from its current price of $9.85.
Amount of Analyst Coverage
Spring Bank Pharmaceuticals has received no research coverage in the past 90 days.

2.2 Community Rank

Outperform Votes
Spring Bank Pharmaceuticals has received 224 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Spring Bank Pharmaceuticals has received 281 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Spring Bank Pharmaceuticals has received 55.64% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote “Outperform” if you believe SBPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Spring Bank Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Spring Bank Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spring Bank Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $833.00 in company stock.
Percentage Held by Insiders
Only 12.70% of the stock of Spring Bank Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 17.17% of the stock of Spring Bank Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Spring Bank Pharmaceuticals are expected to grow in the coming year, from ($1.40) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spring Bank Pharmaceuticals is -5.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spring Bank Pharmaceuticals is -5.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Spring Bank Pharmaceuticals has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SBPH

Previous Symbol

CUSIPN/A

CIK1566373

Webwww.springbankpharm.com

Phone508-473-5993

Employees30

Debt

Debt-to-Equity RatioN/A

Current Ratio5.11

Quick Ratio5.11

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.16 per share

Price / Book4.56

Profitability

EPS (Most Recent Fiscal Year)($1.47)

Net Income$-24,100,000.00

Net MarginsN/A

Return on Equity-89.89%

Return on Assets-52.89%

Miscellaneous

Outstanding Shares17,267,000

Market Cap$170.08 million

Next Earnings DateN/A

OptionableNot Optionable

$9.85

+0.72 (+7.89 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

How has Spring Bank Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Spring Bank Pharmaceuticals' stock was trading at $1.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SBPH shares have increased by 749.1% and is now trading at $9.85.
View which stocks have been most impacted by COVID-19.

Is Spring Bank Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Spring Bank Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SBPH, but not buy additional shares or sell existing shares.
View analyst ratings for Spring Bank Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Spring Bank Pharmaceuticals?

Wall Street analysts have given Spring Bank Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Spring Bank Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Spring Bank Pharmaceuticals' CEO?

1,428 employees have rated Spring Bank Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Spring Bank Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) announced its earnings results on Sunday, November, 8th. The company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.06.
View Spring Bank Pharmaceuticals' earnings history.

What price target have analysts set for SBPH?

2 brokers have issued twelve-month target prices for Spring Bank Pharmaceuticals' shares. Their forecasts range from $1.50 to $2.00. On average, they anticipate Spring Bank Pharmaceuticals' stock price to reach $1.75 in the next twelve months. This suggests that the stock has a possible downside of 82.2%.
View analysts' price targets for Spring Bank Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Spring Bank Pharmaceuticals' key competitors?

Some companies that are related to Spring Bank Pharmaceuticals include Emisphere Technologies (EMIS), Graybug Vision (GRAY), Basilea Pharmaceutica (BPMUF), Rigel Pharmaceuticals (RIGL), Inozyme Pharma (INZY), BELLUS Health (BLUSF), Eagle Pharmaceuticals (EGRX), Veru (VERU), Chinook Therapeutics (KDNY), Ardelyx (ARDX), Oncorus (ONCR), Affimed (AFMD), Homology Medicines (FIXX), Akouos (AKUS) and Spectrum Pharmaceuticals (SPPI).
View all of SBPH's competitors.

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods plc (ABF.L) (ABF), Apollo Global Management (APO), Chaarat Gold Holdings Limited (CGH.L) (CGH), SCYNEXIS (SCYX), Avadel Pharmaceuticals (AVDL) and China Unicom (Hong Kong) (CHU).

Who are Spring Bank Pharmaceuticals' key executives?

Spring Bank Pharmaceuticals' management team includes the following people:

Mr. Martin J. Driscoll, Pres, CEO & Director (Age 61, Pay $568.08k)
Dr. Radhakrishna P. Iyer Ph.D., FRSC, Co-Founder & Chief Scientific Officer (Age 70, Pay $452.04k)
Ms. Lori C. Firmani, VP of Fin., Treasurer, Principal Financial Officer & Principal Accounting Officer (Age 47)
Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
Mr. Garrett Winslow, VP of Legal, Sec. & Gen. Counsel (Age 41)
Dr. Nezam H. Afdhal, Chief Medical Officer (Age 63)
Dr. Atif Abbas, VP and Head of Oncology & Immunology Clinical Devel.

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

How do I buy shares of Spring Bank Pharmaceuticals?

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of SBPH stock can currently be purchased for approximately $9.85.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $170.08 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 30 workers across the globe.

What is Spring Bank Pharmaceuticals' official website?

The official website for Spring Bank Pharmaceuticals is www.springbankpharm.com.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here